Stocktoria
REST EZ Inc. RTEZ
OTC · stock · Pharmaceutical Preparations · website · IPO 2023-02-02
REST EZ Inc. financials (annual, from 10-K)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $5,000 | $0 | $519,443 | $105,000 |
| Gross profit | $0 | $2,450 | $0 | $250,393 | $0 |
| Operating income | -$7,900 | -$19,386 | -$418,408 | $223,642 | -$12,580 |
| Interest expense | $0 | $0 | $10,298 | $9,984 | $10,642 |
| Income tax | $0 | $0 | $0 | $41,687 | $0 |
| Net income | -$7,900 | -$19,386 | -$428,706 | $171,971 | -$23,222 |
| EPS (diluted) | $0.00 | $0.00 | $-0.02 | $0.01 | $0.00 |
| Operating cash flow | -$44,705 | -$103,149 | -$13,312 | -$77,308 | $12,264 |
| Cash & equivalents | $300 | $0 | $44 | $431 | $12,350 |
| Inventory | $0 | $0 | $2,550 | $2,550 | $26,450 |
| Total assets | $300 | $13,500 | $2,594 | $407,981 | $118,950 |
| Shareholders' equity | $300 | -$36,805 | -$170,564 | $247,844 | -$14,111 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | -100.0% | — | -100.0% | +394.7% | — |
| Net income growth | — | — | -349.3% | — | — |
| EPS growth | — | — | -300.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001733861 · US · as of 2025-03-31. facts plus Stocktoria's own computed scores — not investment advice.